[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Jeyou Pharmaceutical Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":63},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100642326","phase-2-a-phase-ii-study-to-evaluate-jmkx000197-injection-versus-cisplatin-in-the-treatment-of-malignant-pleural-effusion-100642326",false,"NCT07649369","A Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion","A Randomized, Controlled, Double-Blind, Multi-center Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion","Inclusion Criteria:\n\n* Participants with advanced solid tumors diagnosed by histopathology or cytopathology.\n* Moderate to large pleural effusions require intervention.\n* ECOG performance status: 0 to 2.\n* Life expectancy ≥ 3 months\n* Adequate organ function.\n* The serum pregnancy test of female participants of childbearing potential should be negative within 7 days prior to enrollment and must not be breastfeeding. With a fertile female\u002Fmale must agree to use medically accepted non-pharmacological contraception during the study and for 6 months after the last dose.\n\nExclusion Criteria:\n\n* Bilateral pleural effusion or concurrent peritoneal effusion, or concurrent pericardial effusion.\n* Pleural effusion is either encapsulated or severely separated; Or merge with chylothorax; Or combined with infectious pleural effusion.\n* Known allergies to the study drug or its excipient components.\n* Have participated in other clinical trials within 28 days prior to randomization.\n* Major surgery within 28 days prior to randomization.\n* Central nervous system metastatic disease, leptomeningeal disease, or cord compression.\n* Clinical unstable or uncontrolled concomitant cardiovascular, pulmonary, hepatic, renal or seizures diseases.\n* Active infections that require systemic treatment.\n* Have a history of organ transplantation.\n* Any further condition which, in the opinion of the Investigator, the participant is not suitable in the present study.","ALL","18 Years","75 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study aims to evaluate the efficacy and safety of intrapleural JMKX000197 compared with intrapleural cisplatin in patients with malignant pleural effusion.",[27],"Malignant Pleural Effusions (Mpe)","NOT_YET_RECRUITING","2026-06-14",{"date":31,"type":32},"2026-06-16","ACTUAL",{"date":34,"type":21},"2026-08-17",{"date":36,"type":21},"2028-08-14",{"name":38,"class":39},"Shanghai Jeyou Pharmaceutical Co., Ltd.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100640423","phase-1-safety-and-efficacy-of-jmkx000189-for-chemotherapy-induced-peripheral-neuropathy-100640423","NCT07601386","Safety and Efficacy of JMKX000189 for Chemotherapy-Induced Peripheral Neuropathy","A Phase Ib Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of JMKX000189 Tablets in Patients With Chemotherapy-Induced Peripheral Neuropathy","Inclusion Criteria:\n\n* Aged 18 to 75 years (inclusive), male or female.\n* Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2.\n* Life expectancy of ≥ 3 months.\n* Histologically or cytologically confirmed malignant solid tumors.\n* Investigator-confirmed diagnosis of CIPN accompanied with chemotherapy.\n* Adequate organ function.\n\nExclusion Criteria:\n\n* Presence of any type of peripheral neuropathy other than CIPN (e.g., diabetic, paraneoplastic, or nutritional).\n* Toxicities from prior anti-tumor therapy (excluding CIPN) \\> CTCAE Grade 1 within 2 weeks of first dose (excluding alopecia, skin pigmentation, stable hypothyroidism, or chronic events).\n* Participants with any of the following cardiovascular diseases or medical history:\n\n  1. Ischemic heart disease or myocardial infarction, unstable angina, coronary artery spasm, congestive heart failure (NYHA Class III-IV), cardiac arrest, stroke, or transient ischemic attack within 6 months;\n  2. Other clinically significant cardiac disorders per investigator's judgment.\n* Presence of active systemic infections.\n* History of or active primary\u002Fsecondary immunodeficiency.\n* Participation in an interventional clinical trial within 1 month prior to screening.\n* Hypersensitivity to any component of the study drug (and its excipients).\n* Any condition deemed by the investigator to pose excessive risk, confound results, or interfere with compliance.",{"count":49,"type":21},18,[51],"PHASE1","This Phase Ib clinical trial aims to evaluate the safety, tolerability, and preliminary efficacy of JMKX000189 tablets in participants with chemotherapy-induced peripheral neuropathy (CIPN).",[54],"CIPN - Chemotherapy-Induced Peripheral Neuropathy","2026-05-15",{"date":57,"type":32},"2026-05-22",{"date":59,"type":21},"2026-05-10",{"date":61,"type":21},"2027-06-20",{"name":38,"class":39},""]